Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th October. Florida-based rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback